Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Loupakis, Fotios; Cremolini, Chiara; Masi, Gianluca; Lonardi, Sara; Zagonel, Vittorina; Salvatore, Lisa; Cortesi, Enrico; Tomasello, Gianluca; Ronzoni, Monica; Spadi, Rosella; Zaniboni, Alberto; Tonini, Giuseppe; Buonadonna, Angela; Amoroso, D.; Chiara, Silvana; Carlomagno, Chiara; Boni, C.; Allegrini, Giacomo; Boni, Luca; Falcone, Alfredo

doi:10.1056/nejmoa1403108

Public

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Published in New England Journal of Medicine • Oct 22, 2014

Authors:

Fotios Loupakis

Chiara Cremolini

Gianluca Masi

Abstract

BACKGROUND: A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy with fluorouracil, leuc...

Subject

Medicine

Bevacizumab

FOLFIRI

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!